TY - JOUR T1 - Induction Chemotherapy with Docetaxel, Cisplatin and Fluorouracil Followed by Surgery and Concurrent Chemoradiotherapy Improves Outcome of Recurrent Advanced Head and Neck Squamous Cell Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 3765 LP - 3773 VL - 34 IS - 7 AU - WEN-CHI YANG AU - CHUNG-HO CHEN AU - JEN-YANG TANG AU - CHIH-FUNG WU AU - YI-CHANG LIU AU - YOUPING SUN AU - SHENG-FUNG LIN Y1 - 2014/07/01 UR - http://ar.iiarjournals.org/content/34/7/3765.abstract N2 - Background: Locally recurrent rate of advanced head and neck squamous cell carcinoma (HNSCC) still remains high and the treatment is controversial. Patients and Methods: We retrospectively analyzed ninety-three patients with recurrent advanced oral cancer from 2009 to 2013. Sixty-four patients are in the docetaxel with cisplatin and 5’-fluorouracil (TPF) group and the remaining twenty-nine patients are in the cisplatin and 5’-fluorouracil (PF) group. Results: The overall response rate was better in the TPF group (p=0.005) than the PF group. Patients who received induction chemotherapy, TPF, followed by surgery and concurrent chemoradiotherapy (CRT) had better overall survival (OS) (p=0.012) and progression-free survival (PFS) (p=0.038), while patients with prior intra-arterial-infusion-chemotherapy had an adverse impact on OS (p=0.039). Conclusion: We showed that induction chemotherapy with TPF, followed by surgery and consolidation CRT, is the ideal choice for recurrent advanced HNSCC with improving response rates and survival. However, prior intra-arterial-infusion-chemotherapy showed an adverse impact. ER -